VIATRIS INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
VIATRIS INC. (VTRS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $38.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $38.70M, a 4.31% increase year-over-year.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $48.20M, a 12.68% decline year-over-year.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $49.40M, a 52.94% increase year-over-year.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $36.00M, a 11.11% increase year-over-year.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $177.70M, a 21.63% increase from fiscal 2024.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $146.10M, a 19.15% decline from fiscal 2023.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $180.70M, a 55.24% increase from fiscal 2022.
- VIATRIS INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $116.40M, a 4.68% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.70M 10-Q · filed 2026-08-06 | $86.90M 10-Q · filed 2026-08-06 | $136.30M derived: sum of 3 quarters · filed 2026-08-06 | $172.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $48.20M 10-Q · filed 2026-05-07 | $97.60M derived: sum of 2 quarters · filed 2026-05-07 | $133.60M derived: sum of 3 quarters · filed 2026-05-07 | $170.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $49.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $85.40M derived: sum of 2 quarters · filed 2026-02-26 | $122.50M derived: sum of 3 quarters · filed 2026-08-06 | $177.70M 10-K · filed 2026-02-26 |
| 2025-09-30 | $36.00M 10-Q · filed 2025-11-06 | $73.10M derived: sum of 2 quarters · filed 2026-08-06 | $128.30M 10-Q · filed 2025-11-06 | $160.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $37.10M 10-Q · filed 2026-08-06 | $92.30M 10-Q · filed 2026-08-06 | $124.60M derived: sum of 3 quarters · filed 2026-08-06 | $157.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $55.20M 10-Q · filed 2026-05-07 | $87.50M derived: sum of 2 quarters · filed 2026-05-07 | $119.90M derived: sum of 3 quarters · filed 2026-05-07 | $154.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $32.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $64.70M derived: sum of 2 quarters · filed 2026-02-26 | $99.40M derived: sum of 3 quarters · filed 2026-02-26 | $146.10M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.40M 10-Q · filed 2025-11-06 | $67.10M derived: sum of 2 quarters · filed 2025-11-06 | $113.80M 10-Q · filed 2025-11-06 | $169.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $34.70M 10-Q · filed 2025-08-07 | $81.40M 10-Q · filed 2025-08-07 | $137.20M derived: sum of 3 quarters · filed 2026-02-26 | $180.30M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $46.70M 10-Q · filed 2025-05-08 | $102.50M derived: sum of 2 quarters · filed 2026-02-26 | $145.60M derived: sum of 3 quarters · filed 2026-02-26 | $184.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $55.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $98.90M derived: sum of 2 quarters · filed 2026-02-26 | $138.10M derived: sum of 3 quarters · filed 2026-02-26 | $180.70M 10-K · filed 2026-02-26 |
| 2023-09-30 | $43.10M 10-Q · filed 2024-11-07 | $82.30M derived: sum of 2 quarters · filed 2024-11-07 | $124.90M 10-Q · filed 2024-11-07 | $154.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $39.20M 10-Q · filed 2024-08-08 | $81.80M 10-Q · filed 2024-08-08 | $111.40M derived: sum of 3 quarters · filed 2025-02-27 | $140.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $42.60M 10-Q · filed 2024-05-09 | $72.20M derived: sum of 2 quarters · filed 2025-02-27 | $101.30M derived: sum of 3 quarters · filed 2025-02-27 | $130.70M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $29.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $58.70M derived: sum of 2 quarters · filed 2025-02-27 | $88.10M derived: sum of 3 quarters · filed 2025-02-27 | $116.40M 10-K · filed 2025-02-27 |
| 2022-09-30 | $29.10M 10-Q · filed 2023-11-08 | $58.50M derived: sum of 2 quarters · filed 2023-11-08 | $86.80M 10-Q · filed 2023-11-08 | $109.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $29.40M 10-Q · filed 2023-08-07 | $57.70M 10-Q · filed 2023-08-07 | $80.20M derived: sum of 3 quarters · filed 2024-02-28 | $105.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $28.30M 10-Q · filed 2023-05-08 | $50.80M derived: sum of 2 quarters · filed 2024-02-28 | $75.80M derived: sum of 3 quarters · filed 2024-02-28 | $106.80M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $22.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $47.50M derived: sum of 2 quarters · filed 2024-02-28 | $78.50M derived: sum of 3 quarters · filed 2024-02-28 | $111.20M 10-K · filed 2024-02-28 |
| 2021-09-30 | $25.00M 10-Q · filed 2022-11-07 | $56.00M derived: sum of 2 quarters · filed 2022-11-07 | $88.70M 10-Q · filed 2022-11-07 | $118.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $31.00M 10-Q · filed 2022-08-08 | $63.70M 10-Q · filed 2022-08-08 | $93.10M derived: sum of 3 quarters · filed 2023-02-27 | $108.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $32.70M 10-Q · filed 2022-05-09 | $62.10M derived: sum of 2 quarters · filed 2023-02-27 | $77.20M derived: sum of 3 quarters · filed 2023-02-27 | $92.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $29.40M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $44.50M derived: sum of 2 quarters · filed 2023-02-27 | $59.80M derived: sum of 3 quarters · filed 2023-02-27 | $79.20M 10-K · filed 2023-02-27 |
| 2020-09-30 | $15.10M 10-Q · filed 2021-11-08 | $30.40M derived: sum of 2 quarters · filed 2021-11-08 | $49.80M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $15.30M 10-Q · filed 2021-08-09 | $34.70M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $19.40M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $56.80M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$3.30M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |